Compare BFS & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BFS | SGMT |
|---|---|---|
| Founded | 1993 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 902.2M | 761.6M |
| IPO Year | 1996 | 2021 |
| Metric | BFS | SGMT |
|---|---|---|
| Price | $28.57 | $9.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $43.00 | $27.91 |
| AVG Volume (30 Days) | 121.8K | ★ 1.2M |
| Earning Date | 11-05-2026 | 11-20-2026 |
| Dividend Yield | ★ 8.19% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $289,843,000.00 | $2,000,000.00 |
| Revenue This Year | $7.44 | N/A |
| Revenue Next Year | $3.40 | N/A |
| P/E Ratio | $58.20 | ★ N/A |
| Revenue Growth | ★ 7.81 | N/A |
| 52 Week Low | $28.56 | $4.50 |
| 52 Week High | $38.42 | $11.45 |
| Indicator | BFS | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 39.14 | 50.81 |
| Support Level | $28.56 | $6.44 |
| Resistance Level | $35.04 | $11.23 |
| Average True Range (ATR) | 0.65 | 0.65 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 22.93 | 42.11 |
Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: Shopping Centers segment, which contribute the maximum portion of total revenue; and mixed-use properties.Mixed-Use Properties segment include office, retail and multi-family residential use.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.